Compare BIO-TECHNE Corp (TECH) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tesla, Inc. — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Tesla, Inc. trades at $379.32 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 124.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| TECH | TSLA | |
|---|---|---|
Market Cap | $11.16B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $72.12 | $489.88 |
52-Week Low | $43.31 | $302.63 |
Enterprise Value | $11.24B | $1.36T |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Tesla trades at $378.99, down 0.49% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows elevated valuation ratios (P/E 339.06, P/S 13.34) despite recent earnings beats in Q4 2025 and Q1 2026. Revenue declined to $94.83B in 2025, with net income margin compressing to 3.95%. Positive developments include regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though delivery misses and competitive pressures weigh on sentiment.
Tesla's outlook balances innovation in autonomy and energy against slowing auto growth and high valuations. The consensus price target of $409.26 suggests modest upside, but risks include execution on robotaxis, margin pressure, and macroeconomic headwinds. Institutional ownership shifts and mixed analyst ratings (38% Buy, 43% Hold) reflect cautious optimism, with the stock's trajectory hinging on AI and energy segments offsetting EV deceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
